Major adverse events (>20%) during lenvatinib therapy were hypertension (n = 171, 49.9% (Grade ≥ 3 n = 14, 4.1%)), decreased appetite (n = 182, n = 53.1% (Grade ≥ 3 n = 9, 2.6%)), fatigue (n = 154, 44.9% (Grade ≥ 3 n = 14, 4.1%)), hand-foot skin reaction (n = 74, 21.6% (Grade ≥ 3 n = 3, 0.9%)), diarrhea (n-91, 26.5% (Grade ≥ 3 n = 3, 0.9%)), and liver-related AEs including increase AST, ALT, or T-Bil (n = 82, 23.9% (Grade ≥ 3 n = 14, 4.1%)). The gene discussed is TBXT; the disease is hypertensive disorder.